Salvage treatments with all-trans retinoic acid and arsenic trioxide-based regimens in acute promyelocytic leukemia / 대한내과학회지
Korean Journal of Medicine
;
: 596-604, 2008.
Artículo
en Coreano
| WPRIM
| ID: wpr-49557
ABSTRACT
BACKGROUND/AIMS:
Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia with a specific clinical and molecular presentation. Treatment of acute promyelocytic leukemia with all-trans retinoic acid or arsenic trioxide in association with anthracyclin has improved outcomes in this disease. We report the results of all-trans retinoic acid and arsenic trioxide-based treatment regimens in acute promyelocytic leukemia patients diagnosed in a single center.METHODS:
Thirty-seven treatment events in 26 patients with acute promyelocytic leukemia were retrospectively reviewed.RESULTS:
Complete remission was achieved in 29 (78.4%) of 37 treatment events. One-year overall survival rate and 1-year event-free survival rate were 74.3% and 66.3%, respectively. Among 16 patients treated with an arsenic trioxide-based regimen, 14 patients (87.5%) achieved complete remission. The 1-year overall survival rate and 1-year event-free survival rate were 78.4% and 69.6%, respectively.CONCLUSIONS:
The short-term use of arsenic trioxide for salvage treatment of acute promyelocytic leukemia seems to be efficacious and could be a bridge to intensive chemotherapy or stem cell transplantation in terms of minimizing the risk of severe disseminated intravascular coagulation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Óxidos
/
Arsénico
/
Arsenicales
/
Tretinoina
/
Leucemia Mieloide Aguda
/
Leucemia Promielocítica Aguda
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Supervivencia sin Enfermedad
/
Trasplante de Células Madre
Tipo de estudio:
Estudio observacional
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS